(Q46873536)

26 December 2017

title

Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder (English)

1 reference

26 December 2017

1 reference

1 reference

placebo-controlled trial

1 reference

Anjana Bose

1

1 reference

26 December 2017

Andrew Korotzer

series ordinal

2

1 reference

26 December 2017

Carl Gommoll

series ordinal

3

1 reference

26 December 2017

Dayong Li

series ordinal

4

1 reference

26 December 2017

publication date

1 January 2008

1 reference

26 December 2017

published in

Depression and Anxiety

1 reference

26 December 2017

volume

25

1 reference

26 December 2017

page(s)

854-861

1 reference

26 December 2017

issue

10

1 reference

26 December 2017

The assessment of anxiety states by rating

cites work

1 reference

Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs

21 January 2018

1 reference

DSM-III-R generalized anxiety disorder in the National Comorbidity Survey.

21 January 2018

1 reference

Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study

21 January 2018

1 reference

7 January 2021

Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

1 reference

7 January 2021

Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study

1 reference

7 January 2021

Escitalopram in the treatment of generalized anxiety disorder

1 reference

7 January 2021

Evidence-based pharmacotherapy of Generalized Anxiety Disorder

1 reference

7 January 2021

A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.

1 reference

7 January 2021

Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder

1 reference

7 January 2021

Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP.

1 reference

7 January 2021

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

1 reference

7 January 2021

Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials

1 reference

7 January 2021

The economic burden of anxiety disorders in the 1990s.

1 reference

7 January 2021

A rating scale for depression

1 reference

7 January 2021

Evidence of the dual mechanisms of action of venlafaxine

1 reference

7 January 2021

1 reference

7 January 2021

A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder

1 reference

7 January 2021

Comorbidity in generalized anxiety disorder

1 reference

7 January 2021

Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine

1 reference

7 January 2021

Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.

1 reference

7 January 2021

Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder.

1 reference

7 January 2021

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

1 reference

7 January 2021

Generalized anxiety disorder: prevalence, burden, and cost to society.

1 reference

7 January 2021

Factors predicting the clinical course of generalised anxiety disorder.

1 reference

7 January 2021

The hospital anxiety and depression scale

1 reference

7 January 2021

Identifiers

DOI

10.1002/DA.20355

1 reference

26 December 2017

PubMed ID

18050245

1 reference

26 December 2017